Unnati Pharmax

Imitikast 100mg Tablet
Composition: Imatinib Mesylate 100mg
International Trade Name: Gleevec®

Imitikast 100 is a premium Imatinib Mesylate 100mg Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Gleevec®. Manufactured in WHO-GMP certified facilities, Imitikast Tablet is supplied by reputable pharmaceutical exporters from India to support effective global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

Imatinib mesylate selectively inhibits the BCR-ABL tyrosine kinase, which drives the proliferation of Philadelphia chromosome-positive CML and other malignancies. Imitikast 100mg Tablet is primarily indicated for the treatment of newly diagnosed or relapsed/refractory Philadelphia chromosome-positive chronic myeloid leukemia, as well as adult patients with KIT (CD117)-positive unresectable and/or metastatic gastrointestinal stromal tumors.

Keywords: Imatinib mesylate 100mg tablet, Imitikast 100 tablet, Gleevec biosimilar, chronic myeloid leukemia treatment, gastrointestinal stromal tumor therapy, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Imitikast 100 Imatinib Mesylate Tablet is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablet is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Imatikast 400mg Tablet
Composition: Imatinib Mesylate 400mg
International Trade Name: Gleevec®

Imatikast 400 is a high-quality Imatinib Mesylate 400mg Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Gleevec®. Manufactured in WHO-GMP certified facilities, Imatikast Tablet is supplied by reputable pharmaceutical exporters from India to support effective global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

Imatinib mesylate selectively inhibits the BCR-ABL tyrosine kinase, which is constitutively active in Philadelphia chromosome-positive CML and certain other malignancies, thereby preventing cancer cell proliferation. Imatikast 400mg Tablet is primarily indicated for the treatment of newly diagnosed or relapsed/refractory Philadelphia chromosome-positive chronic myeloid leukemia, as well as adult patients with KIT (CD117)-positive unresectable and/or metastatic gastrointestinal stromal tumors.

Keywords: Imatinib mesylate 400mg tablet, Imatikast 400 tablet, Gleevec biosimilar, chronic myeloid leukemia treatment, gastrointestinal stromal tumor therapy, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Imatikast 400 Imatinib Mesylate Tablet is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablet is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Imalieva 400mg Tablet
Composition: Imatinib Mesylate 400mg
International Trade Name: Gleevec®

Imalieva 400 is a high-quality Imatinib Mesylate 400mg Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Gleevec®. Manufactured in WHO-GMP certified facilities, Imalieva Tablet is supplied by reputable pharmaceutical exporters from India to support effective global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

Imatinib mesylate selectively inhibits the BCR-ABL tyrosine kinase, which is constitutively active in Philadelphia chromosome-positive CML and certain other malignancies, thereby preventing cancer cell proliferation. Imalieva 400mg Tablet is primarily indicated for the treatment of newly diagnosed or relapsed/refractory Philadelphia chromosome-positive chronic myeloid leukemia, as well as adult patients with KIT (CD117)-positive unresectable and/or metastatic gastrointestinal stromal tumors.

Keywords: Imatinib mesylate 400mg tablet, Imalieva 400 tablet, Gleevec biosimilar, chronic myeloid leukemia treatment, gastrointestinal stromal tumor therapy, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Imalieva 400 Imatinib Mesylate Tablet is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablet is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Tromlieva 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Revolade®

Tromlieva 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Revolade®. Manufactured in WHO-GMP certified facilities, Tromlieva Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that increases platelet production by stimulating the c-Mpl receptor on bone marrow progenitor cells. Tromlieva 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Tromlieva tablets, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Tromlieva 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality control standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Rompag 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Revolade®

Rompag 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Revolade®. Manufactured in WHO-GMP certified facilities, Rompag Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Rompag 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where increased platelet counts are required to enable antiviral therapy.

Eltrombopag 50mg tablets, Rompag tablets, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Rompag 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent potency, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

ELTROMBYRA 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Promacta® / Revolade®

ELTROMBYRA 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand names Promacta® and Revolade®. Manufactured in WHO-GMP certified facilities, ELTROMBYRA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. ELTROMBYRA 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, ELTROMBYRA tablets, Promacta generic, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

ELTROMBYRA 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality control standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Platify 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Platify 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Platify Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Platify 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag 50mg tablets, Platify tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Platify 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent potency, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

ELTROMBYRA 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta® / Revolade®

ELTROMBYRA 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand names Promacta® and Revolade®. Manufactured in WHO-GMP certified facilities, ELTROMBYRA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. ELTROMBYRA 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, ELTROMBYRA tablets, Promacta generic, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

ELTROMBYRA 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Trombonamo 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Revolade®

Trombonamo 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Revolade®. Manufactured in WHO-GMP certified facilities, Trombonamo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Trombonamo 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, Trombonamo tablets, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Trombonamo 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Trombonamo 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Revolade®

Trombonamo 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Revolade®. Manufactured in WHO-GMP certified facilities, Trombonamo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Trombonamo 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Trombonamo tablets, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Trombonamo 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality control standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Revolade 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Revolade 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a branded formulation of the internationally recognized thrombopoietin receptor agonist also marketed under the name Promacta® in several global markets. Manufactured in WHO-GMP certified facilities, Revolade Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that promotes platelet production by stimulating the c-Mpl receptor on bone marrow progenitor cells. Revolade 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to initiate or maintain antiviral therapy.

Eltrombopag 50mg tablets, Revolade tablets, Promacta equivalent, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Revolade 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Trombonat 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Trombonat 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Trombonat Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Trombonat 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, Trombonat tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Trombonat 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Trombonat 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Revolade®

Trombonat 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Revolade®. Manufactured in WHO-GMP certified facilities, Trombonat Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Trombonat 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Trombonat tablets, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Trombonat 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Elromo 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Promacta®

Elromo 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Elromo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Elromo 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Elromo tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Elromo 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Trombonamo 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Promacta®

Trombonamo 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Trombonamo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Trombonamo 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Trombonamo tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Trombonamo 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Eltrog 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Revolade®

Eltrog 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Revolade®. Manufactured in WHO-GMP certified facilities, Eltrog Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Eltrog 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Eltrog tablets, Revolade generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Eltrog 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Rebopag 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Rebopag 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Rebopag Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Rebopag 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, Rebopag tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Rebopag 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Rompag 25mg Tablets
Composition: Eltrombopag Olamine Tablets 25mg
International Trade Name: Promacta®

Rompag 25 is a high-quality Eltrombopag Olamine 25mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Rompag Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Rompag 25mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 25mg tablets, Rompag tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Rompag 25 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Eltrog 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Eltrog 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Eltrog Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Eltrog 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, Eltrog tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Eltrog 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Elromo 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Elromo 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Elromo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Elromo 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, Elromo tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Elromo 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Lenanamo 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Lenanamo 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenanamo Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenanamo 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Lenanamo 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenanamo 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenalid 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Lenalid 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenalid Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenalid 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Lenalid 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenalid 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenangio 25mg Capsule
Composition: Lenalidomide 25mg
International Trade Name: Revlimid®

Lenangio 25 is a high-quality Lenalidomide 25mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenangio Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenangio 25mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 25mg capsule, Lenangio 25 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenangio 25 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Trombonamo 50mg Tablets
Composition: Eltrombopag Olamine Tablets 50mg
International Trade Name: Promacta®

Trombonamo 50 is a high-quality Eltrombopag Olamine 50mg Tablet, a generic equivalent of the internationally recognized thrombopoietin receptor agonist marketed under the brand name Promacta®. Manufactured in WHO-GMP certified facilities, Trombonamo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global hematology and specialty care programs.

Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates platelet production by activating the c-Mpl receptor on bone marrow progenitor cells. Trombonamo 50mg Tablets are primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients with an inadequate response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C, where improvement in platelet counts is required to enable antiviral therapy.

Eltrombopag Olamine 50mg tablets, Trombonamo tablets, Promacta generic, Eltrombopag price, immune thrombocytopenia treatment, platelet booster medicine, hematology drug exporter India, and thrombopoietin receptor agonist manufacturer India.

Trombonamo 50 Eltrombopag Olamine Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Lenalid 25mg Capsule
Composition: Lenalidomide 25mg
International Trade Name: Revlimid®

Lenalid 25 is a high-quality Lenalidomide 25mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenalid Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenalid 25mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 25mg capsule, Lenalid 25 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenalid 25 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenated 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Lenated 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenated Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenated 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Lenated 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenated 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenakast 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Lenakast 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenakast Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenakast 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Lenakast 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenakast 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenangio 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Lenangio 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenangio Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenangio 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Lenangio 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenangio 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenalid 15mg Capsule
Composition: Lenalidomide 15mg
International Trade Name: Revlimid®

Lenalid 15 is a high-quality Lenalidomide 15mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenalid Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenalid 15mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 15mg capsule, Lenalid 15 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenalid 15 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenanamo 25mg Capsule
Composition: Lenalidomide 25mg
International Trade Name: Revlimid®

Lenanamo 25 is a high-quality Lenalidomide 25mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenanamo Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenanamo 25mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 25mg capsule, Lenanamo 25 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenanamo 25 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenalas 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Lenalas 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenalas Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenalas 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Lenalas 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenalas 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Velimide 10mg Capsule
Composition: Lenalidomide 10mg
International Trade Name: Revlimid®

Velimide 10 is a high-quality Lenalidomide 10mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Velimide Capsule is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Velimide 10mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 10mg capsule, Velimide 10 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Velimide 10 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lenalid 5mg Capsule
Composition: Lenalidomide 5mg
International Trade Name: Revlimid®

Lenalid 5 is a high-quality Lenalidomide 5mg Capsule, a trusted biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Revlimid®. Manufactured in WHO-GMP certified facilities, Lenalid Capsule is supplied by reputable pharmaceutical exporters from India to support global oncology treatment programs, particularly in hematologic malignancies.

Lenalidomide modulates the immune system, inhibits angiogenesis, and induces apoptosis in malignant cells, making it highly effective in treating certain cancers. Lenalid 5mg Capsule is primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes (MDS) with deletion 5q, and mantle cell lymphoma, especially in patients who have received prior therapy.

Keywords: Lenalidomide 5mg capsule, Lenalid 5 capsule, Revlimid biosimilar, immunomodulatory agent, multiple myeloma therapy, MDS treatment, mantle cell lymphoma therapy, oncology capsule, biologics exporter India, anticancer small molecule manufacturer India.

Lenalid 5 Lenalidomide Capsule is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dasatib 50mg Tablets
Composition: Dasatinib Tablets 50mg
International Trade Name: Sprycel®

Dasatib 50 is a high-quality Dasatinib 50mg Tablet, a generic equivalent of the internationally recognized tyrosine kinase inhibitor (TKI) marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Dasatib Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib is a second-generation BCR-ABL tyrosine kinase inhibitor that blocks abnormal signaling pathways responsible for uncontrolled proliferation of leukemic cells. Dasatib 50mg Tablets are primarily indicated for the treatment of chronic, accelerated, or blast phase Ph+ CML in patients who are newly diagnosed or resistant or intolerant to prior therapy, including imatinib. It is also used for Ph+ ALL in adults.

Dasatinib 50mg tablets, Dasatib tablets, Sprycel generic, Dasatinib price, chronic myeloid leukemia treatment, tyrosine kinase inhibitor, targeted oncology therapy, anticancer drug exporter India, and leukemia treatment manufacturer India.

Dasatib 50 Dasatinib Tablets are manufactured under stringent GMP and oncology quality standards, ensuring consistent potency, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology-oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dasatib 100mg Tablets
Composition: Dasatinib Tablets 100mg
International Trade Name: Sprycel®

Dasatib 100 is a high-quality Dasatinib 100mg Tablet, a generic equivalent of the internationally recognized tyrosine kinase inhibitor (TKI) marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Dasatib Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib is a second-generation BCR-ABL tyrosine kinase inhibitor that blocks abnormal signaling pathways responsible for uncontrolled proliferation of leukemic cells. Dasatib 100mg Tablets are primarily indicated for the treatment of chronic, accelerated, or blast phase Ph+ CML in patients who are newly diagnosed or resistant or intolerant to prior therapy, including imatinib. It is also used for Ph+ ALL in adults.

Dasatinib 100mg tablets, Dasatib tablets, Sprycel generic, Dasatinib price, chronic myeloid leukemia treatment, tyrosine kinase inhibitor, targeted oncology therapy, anticancer drug exporter India, and leukemia treatment manufacturer India.

Dasatib 100 Dasatinib Tablets are manufactured under stringent GMP and oncology quality standards, ensuring consistent potency, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology-oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dasanat 50mg Tablets
Composition: Dasatinib Tablets IP 50mg
International Trade Name: Sprycel®

Dasanat 50 is a high-quality Dasatinib 50mg Tablet, a generic equivalent of the internationally recognized tyrosine kinase inhibitor (TKI) marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Dasanat Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib is a BCR-ABL tyrosine kinase inhibitor that blocks abnormal signaling pathways responsible for uncontrolled proliferation of malignant cells. Dasanat 50mg Tablets are primarily indicated for the treatment of CML in chronic, accelerated, or blast phases, as well as Ph+ ALL, either in newly diagnosed patients or in those resistant or intolerant to prior therapy including imatinib.

Dasatinib 50mg tablets, Dasanat tablets, Sprycel generic, Dasatinib price, chronic myeloid leukemia treatment, Ph+ ALL therapy, tyrosine kinase inhibitor, oncology drug exporter India, and anticancer drug manufacturer India.

Dasanat 50 Dasatinib Tablets are manufactured under stringent GMP and oncology quality standards, ensuring consistent potency, safety, and long-term stability. The tablets are supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making them suitable for hematology-oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dyronib Tablets
Composition: Dasatinib
International Trade Name: Sprycel®

Dyronib is a high-quality Dasatinib Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Dyronib Tablets are supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib selectively inhibits multiple tyrosine kinases, including BCR-ABL, thereby blocking the proliferation of malignant cells in CML and Ph+ ALL. Dyronib Tablets are primarily indicated for the treatment of adult patients with newly diagnosed or resistant/refractory chronic, accelerated, or blast-phase Philadelphia chromosome-positive chronic myeloid leukemia, as well as Ph+ ALL.

Keywords: Dasatinib tablet, Dyronib tablet, Sprycel biosimilar, tyrosine kinase inhibitor, chronic myeloid leukemia therapy, Ph+ ALL treatment, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Dyronib Dasatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Spnib 100mg Tablet
Composition: Dasatinib 100mg
International Trade Name: Sprycel®

Spnib 100 is a high-quality Dasatinib 100mg Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Spnib Tablets are supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib selectively inhibits multiple tyrosine kinases, including BCR-ABL, thereby blocking the proliferation of malignant cells in CML and Ph+ ALL. Spnib 100mg Tablet is primarily indicated for the treatment of adult patients with newly diagnosed or resistant/refractory chronic, accelerated, or blast-phase Philadelphia chromosome-positive chronic myeloid leukemia, as well as Ph+ ALL.

Keywords: Dasatinib 100mg tablet, Spnib 100 tablet, Sprycel biosimilar, tyrosine kinase inhibitor, chronic myeloid leukemia therapy, Ph+ ALL treatment, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Spnib Dasatinib 100mg Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dasakast 70mg Tablet
Composition: Dasatinib 70mg
International Trade Name: Sprycel®

Dasakast 70 is a high-quality Dasatinib 70mg Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Dasakast Tablets are supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib selectively inhibits multiple tyrosine kinases, including BCR-ABL, thereby blocking the proliferation of malignant cells in CML and Ph+ ALL. Dasakast 70mg Tablet is primarily indicated for the treatment of adult patients with newly diagnosed or resistant/refractory chronic, accelerated, or blast-phase Philadelphia chromosome-positive chronic myeloid leukemia, as well as Ph+ ALL.

Keywords: Dasatinib 70mg tablet, Dasakast 70 tablet, Sprycel biosimilar, tyrosine kinase inhibitor, chronic myeloid leukemia therapy, Ph+ ALL treatment, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Dasakast Dasatinib 70mg Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Invista 100mg Tablet
Composition: Dasatinib 100mg
International Trade Name: Sprycel®

Invista 100 is a high-quality Dasatinib 100mg Tablet, a trusted biosimilar equivalent of the internationally recognized tyrosine kinase inhibitor marketed under the brand name Sprycel®. Manufactured in WHO-GMP certified facilities, Invista Tablets are supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib selectively inhibits multiple tyrosine kinases, including BCR-ABL, thereby blocking the proliferation of malignant cells in CML and Ph+ ALL. Invista 100mg Tablet is primarily indicated for the treatment of adult patients with newly diagnosed or resistant/refractory chronic, accelerated, or blast-phase Philadelphia chromosome-positive chronic myeloid leukemia, as well as Ph+ ALL.

Keywords: Dasatinib 100mg tablet, Invista 100 tablet, Sprycel biosimilar, tyrosine kinase inhibitor, chronic myeloid leukemia therapy, Ph+ ALL treatment, TKI oncology tablet, biologics exporter India, anticancer small molecule manufacturer India.

Invista Dasatinib 100mg Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.